Tata Capital saw a great chance in the fast-growing market for special generic medicines. One of their healthcare-focused private equity funds, Tata Capital Healthcare Fund II, invested a large sum of $20 million into Orbicular Pharmaceutical Technologies for an undisclosed stake. This company specializes in developing specialty generic medicines for the global market. These medicines are cheaper versions of complex brand-name drugs.
What Is The Specialty Generics Market, And Why Is It Booming?
The specialty generics market includes generic medicines that treat complex or rare medical conditions. They are cheaper versions of branded medicines, used to treat common illnesses like high blood pressure or diabetes. Their complex formulations help in treating rarer and complicated diseases or conditions.
The specialty generics market is worth an impressive $60 billion globally. The increasing need for cost-effective options to costly branded medicines drives this growth. As healthcare costs continue to skyrocket, patients and healthcare providers are turning to specialty generics. These medicines are high-quality at a fraction of the cost of their branded equivalents.
What’s Orbicular Pharmaceutical Technologies’ USP?
Orbicular Pharmaceutical Technologies stands out because of its range of niche products in the specialty generics space. The company meets the growing demand for cost-effective options for complex and high-cost branded medicines with its products. With expertise in formulation and drug delivery technologies, Orbicular can develop specialized products that meet critical medical needs because of this expertise.
What Do Experts Say?
Tata Capital Healthcare Fund II’s Managing Partner Visalakshi Chandramouli said, “This investment reinforces our fund’s core philosophy of identifying the big shifts in the industry and being a “capital plus” partner to our companies.”
Dr. Hiren Patel, Chief executive Officer of Orbicular said “This new partnership with Tata Capital Healthcare Fund is a testament to our capabilities and will enable us to accelerate our R&D efforts, expand our portfolio, and strengthen our global partnerships.”
According to M S Mohan, Managing Director of Orbicular Pharmaceutical Technologies, the investment from Tata Capital will fuel product development and strengthen the company’s global partnerships. Securing its position as a unique specialty pharmaceutical company allows Orbicular to use its expertise and create stronger collaborations with partners worldwide.
What Does This Investment Mean For Orbicular And Tata Capital?
Orbicular will use the $20 million investment from Tata Capital Healthcare Fund II to speed up product development. This addition of funds will strengthen Orbicular Pharmaceutical Technologies’ position as a leader in the fast-growing specialty generics landscape.
This investment also shows that Tata Capital is focused on spotting important new trends in industries. They are focused on partnering with companies that are leading the way with new ideas and innovations. Tata Capital’s large investment signals their interest in the growing specialty generics space and their belief in Orbicular’s pioneering work in that area.
Interested In Purchasing Tata Capital Shares?
Tata Capital is not yet a listed company, but it is traded in the grey market or the unlisted share market. Currently, the Tata Capital share price is trading around Rs 1,100 with a potential growth opportunity. At Stockify, you can connect with the team to learn and explore the investment potential of Tata Capital stock price.
We simplify your research and investment process in Unlisted Shares and help you make informed investment decisions. Join our Whatsapp community for regular updates.
